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Patients were treated consecutively in the University 
Hospitals of Leuven between 2005 and 2014 and their data 
were retrospectively retrieved. PORT MPM patients were 
treated with RT doses up to 64 Gy in 2-Gy fractions. PORT 
NSCLC were treated with RT doses up to 60 Gy in 2-Gy 
fractions. Non-surgical patients were treated with RT doses 
up to 66 Gy in 2.75 Gy sequentially with chemotherapy or up 
to 70 Gy in 2 Gy fractions concurrently with chemotherapy. 
Dyspnea scores (CTCAE 4.03) before and after RT were 
retrieved and delta dyspnea was calculated as the difference 
between the dyspnea after RT (worse at any time point) and 
before RT. For every patient, 2 CT scans were retrieved: 1) 
CT0: a free breathing planning CT scan; 2) CT3M: deep 
inspiration breath-hold diagnostic follow up CT scan 3-6 
months after the end of RT. CT0 and CT3M were non-rigidly 
co-registered in MIM. Differences in Hounsfield Unit (delta 
HU=HU3M-HU0) were represented as the slope of the dose-
dependent delta HU between 0 and 20 Gy (expressed in delta 
HU/Gy). Primary endpoint was delta dyspnea >= 2. Univariate 
and multivariate logistic regression analysis were performed 
in order to identify significant predictors of delta dyspnea >= 
2. A p-value of < 0.05 was considered statistically significant.  
 
Results: Delta dyspnea >= 2 was observed in 10/27 patients 
(37%) in the surgical group and in 7/35 patients (20%) in the 
non-surgical group (chi-square test 3.38, p=0.06). Mean delta 
HU/Gy was higher in the surgical group (1.63 vs. 0.67, t-test: 
p=0.04) (see Figure 1). Outcomes of univariate and 
multivariate analysis are showed in Table 1. The model with 
MLD, mean delta HU/Gy and mean heart dose appears to 
better predict a delta dyspnea >= 2 both in the surgical and 
non-surgical group (although not significant). 
 
 
 
 
Conclusion: Surgical patients after PORT are at higher risk of 
developing clinically relevant dyspnea (with a delta >= 2) and 
have a higher increase in lung density (a surrogate of lung 
damage) compared with non-surgical patients. To strengthen 
this hypothesis, we will investigate radiation toxicity after 
more limited surgery (lobectomy) in NSCLC patients. Results 
will be available by the time of the congress. 
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Purpose or Objective: Purpose Data from prospective 
randomized clinical trials are lacking in the comparison 
between lobectomy (LOB) and stereotactic ablative 
Radiotherapy (SABR) in operable patients (pts) and on-going 
trials have troubles in recruiting. In inoperable pts SABR 
achieves a local control of 64-95% in retrospective and 92-98% 
in prospective trials particularly when over 100 Gy Biological 
Equivalent Dose (BED) is delivered. 
 
Material and Methods: From 2010 to 2014, 187 pts with stage 
I-II NSCLC were treated: 133 were male, 54 female. Mean age 
was 72 years. Cyto-histological prove of NSCLC was available 
in 167/187 (89.3%): 111 pts had adenocarcinoma, 51 
squamous cell carcinoma and 3 other histologies. 133 pts 
(71.1%) had stage T1 NSCLC, and 54 (29.9%) stage II NSCLC. 
Ninety-three (49.8%) pts underwent SABR, while ninety-four 
(50.2%) were submitted to LOB. Pts who underwent SABR 
received to 9-20 Gy/die for 3-7 fractions; BED was superior 
than 100 Gy for all treatments. Response to SABR was 
evaluated according to RECIST criteria and toxicity according 
to CTCAE 4.0 scale. To compare LOB vs SABR, we analyzed 
outcomes in terms of Local Control (LC), Tumor-Specific 
Survival (TSS), Metastasis Free Survival (MFS) and Overall 
Survival (OS) using Kaplan-Meier method and log rank tests to 
evaluate differences in time-to-event outcomes between LOB 
and SABR. 
 
Results: At a mean follow up of 23 months (range 6-67), LOB 
showed a better OS (p <0,014) with a 2- and 5-yr OS of 
67,6±5,9% and 34.6±15,7% for SABR and 84.1±4.8% and 
73.4±6.6% for LOB. SABR achieved the same results in terms 
of LC with a 2 and a 5 years LC of 92±3.2% and 80.8±7.9% 
respectively with a p<0,07. Neither significant difference in 
frequency of distant metastasis nor in TSS was observed 
between the two treatment groups (respectively p< 0.41 and 
p<0.50).. In SABR group only 3 G3 lung toxicities were found. 
No other G3 or G4 acute/late toxicity was found. Toxicity 
was minor in SABR group (1 fatigue G1,1 dyspnoea G1,1 
hemoptysis G1); in surgery group we have recorded 7 atrial 
fibrillation, 2 bleeding,1 with death, e 6 prolonged air leak. 
 
Conclusion: SABR using high doses (BED>100) shows similar 
LC than LOB. Very encouraging results in terms of MFS and 
TSS with very few toxicity and no excess of tumor-related 
deaths are obtained with SABR compared with LOB. OS is 
better in LOB group, apparently being strongly influenced by 
the selection of pts addressed to surgery. 
 
Poster: Clinical track: Upper GI (oesophagus, stomach, 
pancreas, liver)  
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Purpose or Objective: Most of trials which established the 
standard treatment of locally advanced oesophageal cancer 
included M0 stage according to the 6th edition of the AJCC 
staging system. Now in the 7th edition of AJCC staging 
system, supraclavicular and celiac lymph node (LN) 
metastasis are no more classified into M1, but considered 
same as other regional LNs. We aimed to evaluate the 
treatment outcomes of NACRT followed by surgery in thoracic 
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esophageal squamous cell carcinoma (ESCC) patients 
including this group of tumors that had been excluded in the 
previous randomized studies. 
 
Material and Methods: A total of 202 patients who were 
diagnosed with stage II-III thoracic ESCC initiated NACRT 
between January 2003 and July 2014. Among them, 9 
patients refused further treatment during the course of 
NACRT and finally 200 patients were analyzed. For clinical 
staging, endoscopic ultrasonography was performed in 116 
(58.0%) and FDG PET/CT in all patients. 75 patients (37.5%) 
had supraclavicular or celiac LN metastasis, which staged as 
M1a (N=54, 27.0%) or M1b (N=21, 10.5%) according to the 6th 
edition of AJCC staging. 168 patients (84.0%) completed both 
NACRT and surgery, 79 (47.0%) of whom underwent 2 field LN 
dissection while 89 (53.0%) received 3 field LN dissection. 
Prognostic factors for survival were assessed using Cox 
regression. 
 
Results: After the median 17.8 months’ follow-up, patients 
(%) experienced disease progression and (%) died. In all 
patients, the 2-year locoregional control (LRC), disease free 
survival (DFS), and overall survival (OS) rates were %, 47.8%, 
and 67.9%, respectively. Following surgery, the pathologic 
complete response was achieved in 44 (26.2%) patients. In 
multivariate analysis, 3 field LN dissection (p=0.0439), ypT0 
(p=0.0380), ypN0 (p=0.0024), and negative surgical margin 
(p=0.0037) were favorable prognostic factors for DFS and 
negative surgical margin (p<0.0001) and age < 60 years 
(p=0.0411) were favorable factors for OS. The metastasis to 
supraclavicular and/or celiac LN was not significant factor for 
and DFS (p=0.5584) and OS (p=0.5874). 
 
Conclusion: Celiac and/or supraclavicular LN metastasis did 
not compromise treatment outcomes significantly following 
NACRT and surgery in selected patients who tolerates the 
trimodality treatment. 
 
PO-0697  
Neoadjuvant vs. adjuvant treatment of gastroesophageal 
junction cancer: a retrospective analysis 
A. Stessin
1Stony Brook University Hospital, Department of Radiation 
Oncology, Stony Brook, USA 
1, J. Miccio2, O. Oladeru2, S. Ryu1 
2Stony Brook University Hospital, Stony Brook University 
School Of Medicine, Stony Brook, USA 
 
Purpose or Objective: Cancer of the gastroesophageal 
junction (GEJ) has been rising in incidence in recent years. 
The role of radiation therapy (RT) in the treatment of GEJ 
cancer remains unclear, as the largest prospective trials 
advocating for either adjuvant or neoadjuvant 
chemoradiotherapy (CRT) combine GEJ cancer with either 
gastric or esophageal cancer. The aim of the present study is 
to examine the effect of neoadjuvant versus adjuvant 
treatment on overall and disease-specific survival for 
patients with surgically resected cancer of the true GEJ 
(Siewert type II). 
 
Material and Methods: The Surveillance, Epidemiology, and 
End Results (SEER) registry database (2001-2011) was queried 
for cases of surgically resected Siewert type II 
gastroesophageal junction cancer. The variables obtained for 
each case include patient demographics (race/ethnicity, sex, 
age at presentation, year of diagnosis), disease 
characteristics (histologic grade, surgical stage/extent of 
disease, nodal status of the disease, presence of distant 
metastases), and treatment modalities (radiation sequence 
relative to surgery, type of surgery performed, and type of 
radiation administered). Patients with metastatic disease, no 
surgical intervention, and missing data were excluded from 
the cohort. 1497 patients with resectable GEJ cancer were 
identified, with 746 receiving adjuvant RT and 751 receiving 
neoadjuvant RT. Retrospective analysis was performed with 
the endpoints of overall and disease-specific survival. 
 
Results: Using cox regression and controlling for independent 
covariates (age, sex, race, stage, grade, histology, and year 
of diagnosis), we showed that adjuvant RT resulted in 
significantly lower death risk (hazard ratio [HR], 0.84; 95% 
confidence interval 0.73-0.97; p-value=0.0168) and 
significantly lower disease-specific death risk (HR, 0.84; 95% 
confidence interval, 0.72-0.97; p-value=0.0211) 
 
Conclusion: This analysis of SEER data showed a survival 
benefit for the use of adjuvant RT over neoadjuvant RT for 
the treatment of Siewert type II GEJ cancer. We suggest 
future prospective studies to compare outcomes of adjuvant 
versus neoadjuvant treatment for true GEJ cancer. 
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Purpose or Objective: We hypothesized that selected cases 
among patients with localized ALN recurrence in gastric 
cancer (GC) might be salvaged by integration of radiotherapy 
(RT) in the multimodal treatment. 
 
Material and Methods: We retrospectively identified patients 
with isolated ALN recurrence from GC between 2005 and 
2013. We categorized patients into two groups by treatment 
approach after diagnosis of ALN recurrence: those who 
treated with integration of RT to chemotherapy (RCT group) 
vs. those who received systemic chemotherapy only (CT 
group). 
 
Results: Of 53 patients with ALN recurrence from GC, 31 
patients were classified as RCT group and 22 as CT group. 
The isolated distant failure (DF; 11/31, 35.5%) was dominant 
pattern of failure (POF) in the RCT group (median DF-free, 26 
months). While local progression (LP) followed by DF (7/22, 
31.8%) was dominant POF in the CT group, in which LP 
(median LP-free, 8 months) occurred earlier than DF (median 
DF-free, 18 months). RCT group had significantly prolonged 
median PFS compared with CT group (25 vs. 8 months, p = 
0.021). In multivariate analysis, the treatment group was 
identified as independent prognostic factor related to PFS (p 
= 0.013). There was a borderline significance in OS between 
RCT group and CT group (29 vs. 20 months, p = 0.095). 
 
Conclusion: Integration of RT and chemotherapy influenced 
the pattern of failure, and significantly improved PFS with 
isolated ALN recurrence in recurrent GC. RT may be 
considered in the treatment course of isolated ALN 
recurrence. 
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Purpose or Objective: To review the treatment result of 
metachronous esophageal cancer (ESC) after head and neck 
cancer (HNC). 
 
